An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: A pilot study

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 909-918

  Wu, Xiang Yuan ^a   Li, Xing ^a   Chen, Zhan Hong ^a   Wen, Jing Yun ^a   Lin, Qu ^a   Xing, Yan Fang ^b   Dong, Min ^a   Wei, Li ^a   Wang, Tian Tian ^a   Chen, Jie ^a   Lin, Ze Xiao ^a   Wan, Xiang Bo ^a   Ruan, Dan Yun ^a   Ma, Xiao Kun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; HBV reactivation; Modified antiviral strategy; Virus breakthrough; Virus relapse

Indexed keywords

ADEFOVIR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; LAMIVUDINE; PREDNISONE; RITUXIMAB; STEROID; VINBLASTINE; VINCRISTINE; ANTIVIRUS AGENT; HEPATITIS ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RETROSPECTIVE STUDY; SIDE EFFECT; VIRUS REACTIVATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; HEPATITIS ANTIGENS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877135462     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0626-6     Document Type: Article

References (35)

1. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9(3):156-66. doi: 10.1038/nrclinonc.2012.1.
2. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008;28(1):28-38. doi: 10.1111/j.1478-3231.2007.01618.x.
3. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89-102. doi: 10.1111/j.1365-2893.2007.00902.x.
4. Li X, Xing YF, Lin Q, Dong M, Wan XB, Wu XY. The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol. 2012;9(6):350; author reply doi: 10.1038/nrclinonc.2012.1-c1.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39. doi: 10.1002/hep.21513.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2. doi: 10.1002/hep.23190.
7. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46(1):254-65. doi: 10.1002/hep.21698.
8. European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010.
9. Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, et al. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma. 2010;51(9):1678-85. doi: 10.3109/10428194.2010.499486.
10. Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transpl. 2006;12(1):84-94. doi: 10.1016/j.bbmt.2005.09.001.
11. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29(2):1237-41. doi: 10.1007/s12032-011-9974-0.
12. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255-62. doi: 10.1007/s00277-009-0806-7.
13. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47(3):844-53. doi: 10.1002/hep.22106.
14. He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol. 2008;87(6):481-5. doi: 10.1007/s00277-008-0454-3.
15. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29(3):889-96. doi: 10.1002/hep.510290321.
16. Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, et al. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 2007;79(2):132-7.
17. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection. 2010;38(1):58-61. doi: 10.1007/s15010-009-9019-1.
18. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106(6):1320-5. doi: 10.1002/cncr.21701.
19. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat. 2004;11(2):141-7.
20. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742-9.
21. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270-5. doi: 10.1007/s00277-003-0825-8.
22. Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci. 2003;18(6):849-54.
23. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002;99(2):724-5.
24. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002;100(2):391-6.
25. Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol. 2009;88(4):375-7. doi: 10.1007/s00277-008-0585-6.
26. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115(1):58-62.
27. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22(5):927-34. doi: 10.1200/JCO.2004.05.161.
28. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther. 2002;16(11):1939-44.
29. Long M, Jia W, Li S, Jin L, Wu J, Rao N, et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011;127(3):705-12. doi: 10.1007/s10549-011-1455-9.
30. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88(3):209-15. doi: 10.1007/s10549-004- 0725-1.
31. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28(4):379-84.
32. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24(6):540-6. doi: 10.1111/j.1478-3231.2004.0964.x.
33. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324-30.
34. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol. 2004;21(1):67-72. doi: 10.1385/MO:21:1:67.
35. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83(12):769-74. doi: 10.1007/s00277-004-0899-y. Province Province Province